



Pharmacy Formulary Updates for January 2020

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status January 2020:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Together MCO- MA
Apriso	NC
Premarin	NC
Menest	NC
Spiriva Respimat 1.25mcg	\$3.65
Trulicity	\$3.65; QL
Lumigan 0.01%	NC
Vyzulta	NC
Travatan Z	NC
Xelpros	NC
Rescula	NC
Zioptan	\$3.65
Repatha	\$3.65; PA; QL
Repatha Pushtronex	\$3.65; PA; QL
Repatha SureClick	\$3.65; PA; QL
Ventolin HFA	NC
Proair HFA	NC
Proventil HFA	NC
Truxima	MB/RX; PA
Annovera	NC; QL
Asceniv	NTM
Brukinsa	NTM
Adakveo	NTM
Amzeeq	NTM
Asparlas	MB/RX

Ogiviri	MB/RX
Fiasp PenFill	NC
Gloperba	NC; QL
Lexette	\$3.65; PA
Givlaari	NTM
Oxbryta	NTM

Key

MB: Medical Benefit

QL: Quantity Limitation

NC: Not covered

SP: Specialty Pharmacy - provided through CVS/specialty

NTM: New-to-market

ST: Step Therapy

PA: Prior Authorization

MB/RX: Drug can be dispensed through Medical Benefit or Prescription Benefit